• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

买一送一：胰高血糖素样肽-1类似物，治疗重度慢性阻塞性肺疾病合并糖尿病患者的新方法。

Two for the price of one: GLP-1 analogues, a new approach in treating severe COPD patients with diabetes.

作者信息

Beech Augusta, Crisafulli Ernesto

机构信息

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

Medicines Evaluation Unit, Manchester, UK.

出版信息

ERJ Open Res. 2025 Apr 14;11(2). doi: 10.1183/23120541.01133-2024. eCollection 2025 Mar.

DOI:10.1183/23120541.01133-2024
PMID:40230433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11995275/
Abstract

https://bit.ly/3PHoygt.

摘要

https://bit.ly/3PHoygt. （此为网址，无法准确翻译为中文，保留原文即可）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/11995275/655ce514d96e/01133-2024.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/11995275/655ce514d96e/01133-2024.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/11995275/655ce514d96e/01133-2024.01.jpg

相似文献

1
Two for the price of one: GLP-1 analogues, a new approach in treating severe COPD patients with diabetes.买一送一：胰高血糖素样肽-1类似物，治疗重度慢性阻塞性肺疾病合并糖尿病患者的新方法。
ERJ Open Res. 2025 Apr 14;11(2). doi: 10.1183/23120541.01133-2024. eCollection 2025 Mar.
2
Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes.降糖药物与2型糖尿病患者慢性阻塞性肺疾病急性加重风险
JAMA Intern Med. 2025 Apr 1;185(4):399-410. doi: 10.1001/jamainternmed.2024.7811.
3
Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.接受单吸入器三联疗法的慢性阻塞性肺疾病患者中基于肠促胰岛素疗法的肺部结局
ERJ Open Res. 2025 Apr 14;11(2). doi: 10.1183/23120541.00803-2024. eCollection 2025 Mar.
4
Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.GLP-1 受体激动剂与 2 型糖尿病患者慢性阻塞性肺疾病加重的相关性。
Am J Respir Crit Care Med. 2023 Nov 15;208(10):1088-1100. doi: 10.1164/rccm.202303-0491OC.
5
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.扩大低收入和中等收入国家2型糖尿病患者获得新型药物的机会：成本效益和价格目标分析
Lancet Diabetes Endocrinol. 2021 Dec;9(12):825-836. doi: 10.1016/S2213-8587(21)00240-0. Epub 2021 Oct 14.
6
Intensifying approach to the therapy of patients with constellation of the diseases: chronic obstructive pulmonary disease and osteoarthritis.针对患有慢性阻塞性肺疾病和骨关节炎这一系列疾病患者的强化治疗方法。
Wiad Lek. 2017;70(3 pt 2):578-580.
7
Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD.靶向性肺去神经支配可调节慢性阻塞性肺疾病中的黏膜上皮转录组。
ERJ Open Res. 2022 Dec 27;8(4). doi: 10.1183/23120541.00146-2022. eCollection 2022 Oct.
8
GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis.GLP-1 类似物作为代谢手术后患者的补充治疗：系统评价和定性综合。
Obes Surg. 2020 Sep;30(9):3561-3569. doi: 10.1007/s11695-020-04750-7. Epub 2020 Jun 5.
9
Large airway wall vascularity in patients with asthma-COPD overlap: a bronchoscopy study.哮喘-慢性阻塞性肺疾病重叠综合征患者的大气道壁血管分布：一项支气管镜检查研究
ERJ Open Res. 2024 Jul 8;10(4). doi: 10.1183/23120541.00002-2024. eCollection 2024 Jul.
10
Current smoking reduces small airway eosinophil counts in COPD.当前吸烟可降低慢性阻塞性肺疾病（COPD）患者的小气道嗜酸性粒细胞计数。
ERJ Open Res. 2024 Jan 22;10(1). doi: 10.1183/23120541.00870-2023. eCollection 2024 Jan.

本文引用的文献

1
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体：作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
2
COPD and multimorbidity: recognising and addressing a syndemic occurrence.COPD 与多种共病：识别和应对综合征发生。
Lancet Respir Med. 2023 Nov;11(11):1020-1034. doi: 10.1016/S2213-2600(23)00261-8. Epub 2023 Sep 8.
3
Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.
GLP-1 受体激动剂与 2 型糖尿病患者慢性阻塞性肺疾病加重的相关性。
Am J Respir Crit Care Med. 2023 Nov 15;208(10):1088-1100. doi: 10.1164/rccm.202303-0491OC.
4
Propensity score methods in observational research: brief review and guide for authors.倾向性评分方法在观察性研究中的应用：简要综述及作者指南。
Br J Anaesth. 2023 Nov;131(5):805-809. doi: 10.1016/j.bja.2023.06.054. Epub 2023 Jul 21.
5
All-Cause, Cardiovascular and Respiratory Mortality in People with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease (COPD) in England: A Cohort Study Using the Clinical Practice Research Datalink (CPRD).在英格兰，2 型糖尿病合并慢性阻塞性肺疾病（COPD）患者的全因、心血管和呼吸道死亡率：一项基于临床实践研究数据库（CPRD）的队列研究。
Int J Chron Obstruct Pulmon Dis. 2023 Jun 13;18:1207-1218. doi: 10.2147/COPD.S407085. eCollection 2023.
6
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease.胰高血糖素样肽-1 受体激动剂在慢性阻塞性肺疾病中的作用。
Int J Chron Obstruct Pulmon Dis. 2023 Feb 15;18:129-137. doi: 10.2147/COPD.S393323. eCollection 2023.
7
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.迈向消除慢性阻塞性肺疾病：柳叶刀委员会报告。
Lancet. 2022 Sep 17;400(10356):921-972. doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5.
8
Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD?COPD 与 1 型和 2 型糖尿病的关联机制：糖尿病与 COPD 之间存在关联吗？
Medicina (Kaunas). 2022 Aug 1;58(8):1030. doi: 10.3390/medicina58081030.
9
Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.肥胖症与慢性阻塞性肺疾病患者使用胰高血糖素样肽-1 受体激动剂治疗的呼吸效应。
Int J Chron Obstruct Pulmon Dis. 2022 Feb 22;17:405-414. doi: 10.2147/COPD.S350133. eCollection 2022.
10
Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.利拉鲁肽改善 2 型糖尿病患者的用力肺活量：来自随机交叉 LIRALUNG 研究的数据。
Diabetes. 2022 Feb 1;71(2):315-320. doi: 10.2337/db21-0688.